Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
185 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02308527 | Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children(BEACON) | completed | Phase 2 | 225 | University of BirminghamOTHER | 10 | May 12, 2026 | clinicaltrials |
| NCT06898450 | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 134 | Nimbus Wadjet, Inc.INDUSTRY | 8 | May 6, 2026 |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | active not recruiting | Phase 2 | 251 | Cancer Trials IrelandNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01164150 | Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06 | terminated | Phase 2 | 92 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | terminated | Phase 1 / Phase 2 | 94 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02160353 | Neo-adjuvant Abiraterone Prostate Study | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02225704 | Radium-223 in Combination With Enzalutamide | completed | Phase 2 | 45 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02764086 | INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer | terminated | Phase 1 / Phase 2 | 6 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03869762 | Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.(DICE) | terminated | Phase 2 | 7 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With Metastatic Refractory Pancreatic Cancer(PaTcH) | terminated | Phase 2 | 20 | Cancer Trials IrelandNETWORK | 1 | Apr 13, 2026 | clinicaltrials |
| NCT04262466 | Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | active not recruiting | Phase 1 / Phase 2 | 410 | Immunocore LtdINDUSTRY | 17 | Mar 6, 2026 | clinicaltrials |
| NCT05896566 | A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer(PREcoopERA) | completed | Phase 2 | 231 | ETOP IBCSG Partners FoundationNETWORK | 6 | Feb 24, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT04704219 | Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)(KEYNOTE-B61) | completed | Phase 2 | 160 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Dec 3, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT02060188 | A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread(CheckMate142) | completed | Phase 2 | 385 | Bristol-Myers SquibbINDUSTRY | 8 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT04003610 | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) | terminated | Phase 2 | 7 | Incyte CorporationINDUSTRY | 16 | Nov 4, 2025 | clinicaltrials |
| NCT04260126 | Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC(VERSATILE002) | completed | Phase 2 | 95 | PDS Biotechnology Corp.INDUSTRY | 4 | Oct 1, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT02007512 | Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer | completed | Phase 2 | 247 | PfizerINDUSTRY | 7 | Sep 2, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT00812669 | CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | completed | Phase 2 | 52 | Cancer Trials IrelandNETWORK | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT04375904 | 'SOURCE - LUNG' Stereotactic Ablative Radiation Therapy Of UltRaCEntral LUNG Tumours (SOURCE Lung)(SOURCE Lung) | recruiting | Phase 2 | 68 | Cancer Trials IrelandNETWORK | 1 | May 2, 2025 | clinicaltrials |
| NCT06078813 | Spine SABR - Dose-escalated Stereotactic Ablative Body Radiotherapy (SABR) for Solid Tumour Spine Metastases(Spine-SABR) | recruiting | Phase 1 / Phase 2 | 126 | Cancer Trials IrelandNETWORK | 1 | Apr 30, 2025 | clinicaltrials |
| NCT04630756 | AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer | completed | Phase 1 / Phase 2 | 40 | AstraZenecaINDUSTRY | 9 | Apr 9, 2025 | clinicaltrials |
| NCT02927769 | A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment(CheckMate 744) | completed | Phase 2 | 72 | Bristol-Myers SquibbINDUSTRY | 11 | Feb 10, 2025 | clinicaltrials |
| NCT01889238 | Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer | completed | Phase 2 | 118 | PfizerINDUSTRY | 7 | Dec 13, 2024 | clinicaltrials |
| NCT00626106 | QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer | completed | Phase 2 | 156 | NantCell, Inc.INDUSTRY | 9 | Sep 19, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT01660451 | Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas | completed | Phase 2 | 227 | BayerINDUSTRY | 25 | Jul 17, 2024 | clinicaltrials |
| NCT02676986 | Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer(ARB) | completed | Phase 2 | 221 | Queen Mary University of LondonOTHER | 5 | Jul 5, 2024 | clinicaltrials |
| NCT01796171 | A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma(LYMRIT-37-01) | completed | Phase 1 / Phase 2 | 191 | Nordic NanovectorINDUSTRY | 24 | Jun 21, 2024 | clinicaltrials |
| NCT04625907 | FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma(FaR-RMS) | recruiting | Phase 1 / Phase 2 | 1,672 | University of BirminghamOTHER | 20 | May 23, 2024 | clinicaltrials |
| NCT04793919 | Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia | recruiting | Phase 2 | 89 | Associazione Italiana Ematologia Oncologia PediatricaOTHER | 12 | Apr 15, 2024 | clinicaltrials |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations(SUMMIT) | terminated | Phase 2 | 582 | Puma Biotechnology, Inc.INDUSTRY | 13 | Mar 12, 2024 | clinicaltrials |
| NCT04617067 | Paricalcitol Trial: Phase II, Open Label Clinical Trial of Paricalcitol in Combination With Gemcitabine/ Nab-Paclitaxel Therapy in Advanced Pancreatic Cancer | completed | Phase 2 | 15 | Cancer Trials IrelandNETWORK | 1 | Mar 6, 2024 | clinicaltrials |
| NCT03230318 | Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma(FIDES-01) | completed | Phase 2 | 148 | Basilea PharmaceuticaINDUSTRY | 11 | Dec 19, 2023 | clinicaltrials |
| NCT03997643 | Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial | recruiting | Phase 2 | 90 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 4 | Aug 3, 2023 | clinicaltrials |
| NCT02952534 | A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency(TRITON2) | completed | Phase 2 | 277 | pharmaand GmbHINDUSTRY | 12 | Jun 9, 2023 | clinicaltrials |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208) | completed | Phase 2 | 98 | Seagen Inc.INDUSTRY | 6 | May 6, 2023 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials